Cold Spring Harbor, NY – Scientists at Cold Spring Harbor Laboratory (CSHL) have discovered that cells lacking the tumor-suppressor protein PTEN–a feature of many cancers– are particularly vulnerable to drugs that impair their energy-producing mitochondria. Such drugs induce them to literally eat themselves to death, the research shows. Unlike normal cells, cells without PTEN seem … Continued
–Versant-seeded company focused on applying novel biology to boost anti-tumor immunity– —Foundational science stems from landmark ER stress biology research at Weill Cornell Medicine— —Michael Aberman, M.D., former SVP of Strategy for Regeneron, appointed as President and Chief Executive Officer— NEW YORK–(BUSINESS WIRE)–Quentis Therapeutics Inc., a biotechnology company pursuing next-generation immuno-oncology research and drug development, … Continued
Researchers at the Sloan Kettering Institute and the Weill Cornell Graduate School of Medical Sciences in New York have developed a machine learning approach to design personalized nanoparticle therapies for cancer. Personalized cancer therapies aim to provide a treatment that is tailored to the genetic makeup of a patient’s tumor. They can still cause side effects, however, when they … Continued
Far from her native Copenhagen, Denmark, Mikala Egeblad, PhD, works tirelessly to find a means to reduce cancer metastases and recurrences. The significance of her work, now centered in her lab at Cold Spring Harbor Laboratory, Long Island, N.Y., where she is an Associate Professor, has resulted in the Department of Defense Breast Cancer Research … Continued
Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes after infectious microorganisms. Yet these treatments only benefit some patients, and remain ineffective in the vast majority of cases. … Continued
PUBLIC RELEASE: 8-JAN-2018 Cold Spring Harbor, NY – Cancer researchers today announced they have developed a way of sidelining one of the most dangerous “bad actors” in leukemia. Their approach depends on throwing a molecular wrench into the gears of an important machine that sets genes into motion, enabling cancer cells to proliferate. In tests in … Continued
October 9, 2017—BRONX, NY—Scientists at Albert Einstein College of Medicine have discovered the first compound that directly makes cancer cells commit suicide while sparing healthy cells. The new treatment approach, described in today’s issue of Cancer Cell, was directed against acute myeloid leukemia (AML) cells but may also have potential for attacking other types of cancers. “We’re hopeful … Continued
After 18 months being incubated by Versant Ventures, upstart Repare Therapeutics has emerged from stealth mode with an impressive $68 million, backing from Celgene and some big-name execs. The Montreal and Cambridge, Massachusetts, biotech saw founding investor Versant Ventures co-lead the series A round with MPM Capital. They were also joined by other syndicate investors … Continued
Researchers from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center have received two grants from the Sohn Conference Foundation to advance their investigation into how cancer spreads in children. Dr. David Lyden, the Stavros S. Niarchos Professor in Pediatric Cardiology and a professor of pediatrics, Dr. Haiying Zhang, an assistant professor of cell and … Continued
Some people struggle to find their paths in life. Not Chris Mason, PhD, Associate Professor and geneticist at Weill Cornell Medicine in New York City. He had already determined he wanted to be a geneticist by the time he reached eighth grade. “I was—and still am—a curious kid. I wanted to know how the world … Continued